8月7日 - ** Exact Sciences EXAS.O下跌10%至42.20美元，此前血液结直肠癌$(CRC)$ 测试未达到试验预期
** 经纪公司BTIG称这是 "最坏的情况"。
** 这也给 (link) 的强劲增长和第二季度的加薪蒙上了阴影。
** EXAS 周三与 (link) 签订协议，获得 Freenome 基于血液的 CRC 筛查测试的独家经营权，但分析师指出该协议不包括多种癌症测试，这令投资者感到失望。
** 至少六家券商下调目标股价
** 竞争对手 Guardant Health GH.O 的股价上涨近 17
** Canaccord Genuity称GH的Shield测试表现略好于Freenome的测试
** EXAS的股价今年以来下跌了27%，而GH则大涨了近70
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.